Invasive treatment for renovascular disease. A twenty year experience from a population based registry

Department of Surgical Sciences, Section of Surgery, Uppsala University Hospital Uppsala, Sweden.
The Journal of cardiovascular surgery (Impact Factor: 1.46). 10/2008; 49(5):559-63.
Source: PubMed


To analyze time trends in invasive treatment of renovascular disease in one country.
Data have been analyzed from registrations in the Swedish Vascular Registry.
Invasive treatment for renovascular disease contributes around 1% of all vascular surgery within the Swedish Vascular Registry. Over the twenty-year period 1987-2006 the population-based frequency of invasive treatment for renovascular disease has increased; 1 597 procedures have been registered with an increase over time. The age of the treated patients has increased over the period (P<0.001). There has been a shift from open to endovascular procedure and from isolated percutaneous transluminal renal angioplasty (PTRA) to PTRA combined with a stent. Complications and mortality are significantly higher in patients undergoing open reconstruction (P<0.01). One year follow-up is incomplete and long-term results are therefore not possible to evaluate through registry-data only.
Using nation-wide registry data it is possible to analyze time-trends also concerning rare diseases or interventions. The changing pattern toward endovascular treatment of renovascular disease is obvious. Follow-up data at one year are incomplete.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: to analyze the presentations given at the annual meeting of European Society for Vascular Surgery: topic, geographical distribution, later publication. Three six-year periods from 1989 have been evaluated. case series dominates but randomized trials have increased somewhat. Papers on animal experiments and basic science have decreased. The most frequently reported diseases have been aortic aneurysm, carotid artery problems, lower extremity ischaemia and with an increasing number of papers on venous disease. Around two thirds of the presentations have been later published as full papers in European Journal of Vascular and Endovascular Surgery, but as many as one quarter has not been published. Geographical origin has varied over time with a decrease in the UK dominance. The presentations at the Annual meeting of European Society for Vascular Surgery contribute substantially to the contents of the Society Journal but a large proportion of the presentations never appear in print. Northern Europe dominates when papers per population unit is counted.
    European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 08/2008; 36(1):114-7. DOI:10.1016/j.ejvs.2008.01.012 · 2.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With an aging population, more patients might be treated for atherosclerotic renal artery stenosis (ARAS). The goal of this treatment is to achieve a dialysis-free life or a well-controlled blood pressure with reduced risks of cardiovascular complications. To analyze the clinical outcome of percutaneous transluminal renal artery angioplasty without stenting (PTRA) or with stenting (PTRS) for ARAS at one center. The study group comprised 152 patients who underwent 203 PTRA/PTRS. All had hypertension, and 45% had azotemia. A retrospective collection of baseline and postprocedural number of antihypertensive drugs, blood pressure, and serum creatinine were analyzed during a follow-up of 3-18 months. Technical success rate was 95%, and clinical benefit was seen in 63% of patients. Complications included a 30-day mortality rate of 1.5%, a total complication rate of 35%, and major adverse events in 13%. The major adverse events were highly related to azotemia. Major adverse events within 30 days, with permanent disability, were seen in 5% and almost exclusively in patients with moderate or severe renal impairment. A subgroup analysis of 28 patients with renal duplex resistive index (RI) pre-PTRA/S and 6 months' follow-up showed a benefit of PTRA/PTRS in 17 (68%) of the 25 patients with RI <80 and in all three (100%) of the patients with RI >or=80. Endovascular treatment of ARAS has an excellent technical success rate, with a clinical improvement rate of >60%. However, it is associated with a considerable complication rate. Serious complications are seen mainly in azotemic patients. Predictors of clinical response could not be identified. Renal duplex RI is questioned as a predictor of clinical outcome.
    Acta Radiologica 02/2009; 50(3):256-64. DOI:10.1080/02841850802668563 · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The management of renal artery stenosis (RAS) remains controversial. There is a large body of evidence from registries and cohort studies suggesting that revascularisation with stenting is beneficial in RAS; however, randomised trials of revascularisation versus medical therapy have failed to demonstrate that revascularisation improves outcome. Owing to significant methodological limitations, recent randomised trials have increased the controversy instead of resolving it, yet these trials cannot be disregarded. Currently, there appears to be a role for stenting in RAS, particularly among patients with at least moderate chronic kidney disease who seem to derive the greatest benefit from stenting. Additionally, there is probably some degree of blood pressure improvement; however, in most cases, stenting does not provide a cure. Thus, it is important that a physician evaluates each patient with RAS carefully and considers multiple issues to determine whether stenting would be beneficial.
    Interventional Cardiology (London) 04/2011; 6(1):89. DOI:10.15420/ICR.2011.6.1.89
Show more